| Sodium–glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study A Douros, LM Lix, M Fralick, S Dell'Aniello, BR Shah, PE Ronksley, ... Annals of Internal Medicine 173 (6), 417-425, 2020 | 130* | 2020 |
| Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study KB Filion, LM Lix, HY Oriana, S Dell’Aniello, A Douros, BR Shah, ... bmj 370, 2020 | 102* | 2020 |
| Clinical research needs for the management of chronic rhinosinusitis with nasal polyps in the new era of biologics: a National Institute of Allergy and Infectious Diseases Workshop R Naclerio, F Baroody, C Bachert, B Bleier, L Borish, E Brittain, G Chupp, ... The Journal of Allergy and Clinical Immunology: In Practice 8 (5), 1532-1549. e1, 2020 | 48 | 2020 |
| Comparative persistence of the TNF antagonists in rheumatoid arthritis–a population-based cohort study A Fisher, K Bassett, JM Wright, MA Brookhart, H Freeman, CR Dormuth PLoS One 9 (8), e105193, 2014 | 43 | 2014 |
| Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study OHY Yu, S Dell’Aniello, BR Shah, VC Brunetti, JM Daigle, M Fralick, ... Diabetes Care 43 (10), 2444-2452, 2020 | 31* | 2020 |
| Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study N Daneman, D Chateau, M Dahl, J Zhang, A Fisher, IS Sketris, J Quail, ... Clinical Microbiology and Infection 26 (5), 613-618, 2020 | 27 | 2020 |
| Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort CR Dormuth, B Winquist, A Fisher, F Wu, P Reynier, S Suissa, M Dahl, ... JAMA network open 4 (4), e215329-e215329, 2021 | 24 | 2021 |
| Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort … M Durand, ME Schnitzer, M Pang, G Carney, S Eltonsy, KB Filion, ... Canadian Medical Association Open Access Journal 8 (4), E877-E886, 2020 | 23 | 2020 |
| Tolerability of cholinesterase inhibitors: a population-based study of persistence, adherence, and switching A Fisher, G Carney, K Bassett, CR Dormuth Drugs & aging 34 (3), 221-231, 2017 | 23 | 2017 |
| Weight and inflammation are the major determinants of vascular dysfunction in the aortae of db/db mice N Sallam, A Fisher, S Golbidi, I Laher Naunyn-Schmiedeberg's archives of pharmacology 383 (5), 483-492, 2011 | 22 | 2011 |
| Sodium‐glucose co‐transporter‐2 inhibitors and the risk of urosepsis: A multi‐site, prevalent new‐user cohort study A Fisher, M Fralick, KB Filion, S Dell'Aniello, A Douros, É Tremblay, ... Diabetes, Obesity and Metabolism 22 (9), 1648-1658, 2020 | 16 | 2020 |
| Cholinesterase inhibitor utilization: the impact of provincial drug policy on discontinuation A Fisher, G Carney, K Bassett, NL Chappell Value in Health 19 (5), 688-696, 2016 | 12 | 2016 |
| Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort A Fisher, K Bassett, JM Wright, MA Brookhart, HJ Freeman, CR Dormuth BMJ open 4 (9), e005532, 2014 | 11 | 2014 |
| Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study LM Lix, S Sobhan, A St-Jean, JM Daigle, A Fisher, OHY Yu, S Dell’Aniello, ... BMC Health Services Research 21 (1), 1-11, 2021 | 10 | 2021 |
| Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi‐database cohort study with meta‐analysis M Durand, ME Schnitzer, M Pang, G Carney, S Eltonsy, KB Filion, ... British journal of clinical pharmacology 87 (6), 2589-2601, 2021 | 10 | 2021 |
| Tofacitinib persistence in patients with rheumatoid arthritis: a retrospective cohort study A Fisher, M Hudson, RW Platt, CR Dormuth The Journal of Rheumatology 48 (1), 16-24, 2021 | 9 | 2021 |
| Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia—An interim report A Fisher, JD Kim, CR Dormuth Pharmacoepidemiology and Drug Safety 29 (7), 803-810, 2020 | 8 | 2020 |
| A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia CR Dormuth, A Fisher, G Carney Pharmacoepidemiology and drug safety 29 (7), 796-802, 2020 | 8 | 2020 |
| Heterogeneity in comparisons of discontinuation of tumor necrosis factor antagonists in rheumatoid arthritis-a meta-analysis A Fisher, K Bassett, G Goel, D Stanely, MA Brookhart, HR Freeman, ... PloS one 11 (12), e0168005, 2016 | 8 | 2016 |
| Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia A Fisher, JD Kim, G Carney, C Dormuth BMC rheumatology 6 (1), 1-9, 2022 | 6 | 2022 |
Pierre ErnstProfessor of Medicine, McGill UniversityVerified email at mcgill.ca
